Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 12/20 | 0.56 |
| ▸ | F10 | P00742 | 12/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 12/20 | 0.56 |
| ▸ | F9 | P00740 | 1/20 | 0.55 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7368198 | 0.84 | F2 (0.59) | F2F10PRSS1F9RAB9A | |
| SCHEMBL6616732 | 0.83 | F10 (0.78) | F2F10PRSS1F9 | |
| SCHEMBL7217821 | 0.75 | NPC1 (0.46) | F10PARP14CA1CA2MAPT | |
| SCHEMBL1982997 | 0.72 | F10 (1.00) | F2F10PRSS1F9 | |
| SCHEMBL7367326 | 0.71 | F10 (1.00) | F2F10PRSS1F9 | |
| SCHEMBL4485828 | 0.70 | TSHR (0.64) | CDK2 | |
| SCHEMBL4478874 | 0.68 | SLC6A4 (0.53) | — | |
| SCHEMBL7365282 | 0.68 | F10 (0.81) | F2F10PRSS1F9 | |
| SCHEMBL20846094 | 0.68 | HTR6 (0.46) | PARP14 | |
| SCHEMBL18229447 | 0.67 | MAPT (0.57) | MEN1MAPTSTAT3RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015429-B1 | BENZIMIDAZOLINONES, BENZOXAZOLINONES, BENZOPIPERAZINONES, INDANONES, AND DERIVATIVES THEREOF AS INHIBITORS OF FACTOR XA | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-05-12 | — | — | EP | disclosed |
| US-6552042-B2 | Anticoagulants | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-22 | — | — | US | disclosed |
| US-20010021775-A1 | Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor Xa | HAN QI (US) | 2001-09-13 | — | — | US | disclosed |
| US-6207697-B1 | AMIDINYL-SUBSTITUTED RINGS; ANTICOAGULANTS; THROMBOEMBOLIC DISORDERS; ANTIISCHEMIC AND ANTIINFLAMMATORY AGENTS; STROKES; SERINE PROTEASE INHIBITORS | DUPONT PHARMACEUTICALS COMPANY | 2001-03-27 | — | — | US | disclosed |
| EP-1015429-A1 | BENZIMIDAZOLINONES, BENZOXAZOLINONES, BENZOPIPERAZINONES, INDANONES, AND DERIVATIVES THEREOF AS INHIBITORS OF FACTOR XA | Du Pont Pharmaceuticals Company (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999012903-A1 | BENZIMIDAZOLINONES, BENZOXAZOLINONES, BENZOPIPERAZINONES, INDANONES, AND DERIVATIVES THEREOF AS INHIBITORS OF FACTOR XA | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021775-A1 | Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor Xa | F12, F13B, F11 | F2 4/4885F10 10/4885PRSS1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.